Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service 8-28-17

|About: ACADIA Pharmaceuticals Inc. (ACAD), AMGN, AMRN, CVRS, PRQR, RDUS, Includes: LLY

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these Monday blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: (ACAD)

Checking In On Acadia Pharma's (ACAD) NUPLAZID For Hallucinations And Delusions Associated With Parkinson's Disease Psychosis One Year Into The Launch

Call Date: 11:00am 7/20/17

Who's the Expert:

  • Professor of Neurology & Director of the Parkinson's Disease and Movement Disorder Center at the University of Kansas Medical Center. 
  • Research interests are centered around the various aspects of Parkinson's disease and essential tremor. He currently treats 200 patients with PDP with ~75 prescribed Nuplazid.
  • Has published more than 250 peer-reviewed articles, chapters and abstracts in leading neurology and movement disorder journals. He has conducted more than 75 clinical trials related to Parkinson's disease and other movement disorders. 

Interview Goal: 

To give investors a better understanding of the success of NUPLAZID since its launch in June 2016. NUPLAZID is the first FDA approved drug for hallucinations and delusions associated with psychosis from Parkinson's disease.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 2: (AMRN)

Understanding how Vascepa fits in the prescription-based, pure EPA market in treating hypertriglyceridemia

Call Date: 1:00pm on 7/28/18

Who's the Expert:

  • Professor of Medicine and Endowed Chair of Preventive Cardiology at UCLA.
  • Treats hundreds of patients with hypertriglyceridemia, has prescribed Vascepa, and  has been in practice 25 years advancing procedures that can help doctors identify cardiac patients early and place them on a therapeutic path to prevent a heart attack.
  • Works on at least 20 active medical research trials at any given time, and has authored or co-authored over 800 research papers, seven books, and 45 book chapters. 

Interview Goal:

To analyze the data leading up to the REDUCE-IT trial completion and compare Vascepa to the alternatives on the market.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 3: (PRQR)

Exploring the potential of ProQR Therapeutics' (PRQR) Cystic Fibrosis drug QR-010 after its Proof-Of-Concept Trial

Call Date: 10:00AM 7/31/17

Who's the Expert?

  • Former Director of the Cystic Fibrosis Center at Stanford and site principal investigator (PI) for the Cystic Fibrosis Therapeutics Development Network. Currently serves as a member of Stanford’s Child Health Research Institute and the Executive Committee of Stanford’s NIH clinical research program (Spectrum Child Health) and the Stanford IRB.
  • Currently treats ~20 patients with cystic fibrosis at an academic center where 80% CF patients have at least 1 f508 allele and ~40% have two (homozygous).
  • Has reviewed and consulted for the NIH, CFF, national and international foundations, peer-reviewed journals and biopharmaceutical companies. Research interests include pathogenesis, outcome measures, and treatment of chronic airway diseases of childhood.

Interview Goal: 

To get a better understanding of QR-010's proof-of-concept data and get an expert's view on whether or not the drug has the makings to become a headlining treatment for Cystic Fibrosis. Aspects such as current treatment, side effect and convenience issues, and overall need for the product will also be discussed.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 4 (RDUS, AMGN, LLY)

A Second Expert Opinion on Radius' (RDUS) Market Potential for Recently Approved Osteoporosis Drug TYMLOS (abaloparatide)

Call Date: 11:00am 08/03/2017

Who's the Expert:

  • Professor of Medicine and Jerry W. and Peg S. Throgmartin Professor of Oncology in the Department of Medicine, Division of Endocrinology at Indiana University.
  • Directs a metabolic bone disease clinic at IU where all of the patients have bone disease and a majority are postmenopausal women. Treats ~10-12 patients/week with injectable osteoporosis drugs (anti-resorptives denosumab and reclast or anabolics forteo or abaloparatide).
  • Clinical interests include diseases of calcium and bone metabolism, and has been the recipient of numerous grants for research on the skeletal health in cancer patients. Dr. Guise is a frequent lecturer and has been published in over 100 peer reviewed journals.

Interview Goal:

Get a second expert opinion on the market potential for Radius' (RDUS) recently approved osteoporosis drug abaloparatide in wake of Amgen's (AMGN) recent rejection for a drug targeting the same patient cohort and the ongoing RDUS trials for a transdermal abaloparatide delivery system. 

Link to original project page on Slingshot Insights with questions asked: link

Transcript 5 (CVRS)

Analyzing the Market Share of Corindus’ CorPath GRX Vascular Robotics Technology and the Competitive Landscape in Robotic-assisted PCI Surgery

Call Time: 5:00PM 08/01/2017

Who's the Expert?

  • Assistant Professor, Cardiology specializing in Interventional Cardiology and Endovascular Interventions.
  • Co-investigator in numerous clinical trials and has published numerous research articles in peer reviewed renowned medical journals/book chapters. 
  • Board certified in Internal Medicine, Cardiology, Interventional Cardiology, Vascular Medicine and Endovascular Medicine. He is also certified in Adult Comprehensive Echocardiography and American Registry for Diagnostic Medical Sonography (ARDMS).

Interview Goal:

To gain a better understanding of CorPath GRX, its impact on the market, and how it compares to traditional angioplasty and other Robotic-assisted percutaneous coronary intervention (PCI) devices on the market.

Link to original project page on Slingshot Insights with questions asked: link

###
Become the newest subscriber to “Become the Smart Money” here and gain access to all of these interview and more : Link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.